Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06414460 · ClinicalTrials.gov registry record · Phase 1
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
A Phase 1 study of Locally Advanced/Metastatic Solid Tumors, sponsored by InSilico Medicine Hong Kong Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 9
- Study locations
NCT06414460: Recruiting Phase 1 study of Locally Advanced/Metastatic Solid Tumors, sponsored by InSilico Medicine Hong Kong Limited.
NCT06414460 is a Phase 1 study of Locally Advanced/Metastatic Solid Tumors that is actively recruiting participants, run by InSilico Medicine Hong Kong Limited. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06414460, a Phase 1 study of Locally Advanced/Metastatic Solid Tumors, is actively recruiting participants, sponsored by InSilico Medicine Hong Kong Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 9
- Study locations
Study Summary
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
Primary Outcome
To evaluate the safety and tolerability of ISM3412.
Conditions Studied
Interventions
- DRUG ISM3412
Study Locations (9)
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Smilow Cancer Hospital at Yale New Haven Breast Center - New Haven
Indiana
- Community Cancer Center North - Indianapolis
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
Guangdong
- Sun Yat-sen university cancer center - Guangzhou
Jiangsu
- Jiangsu Provincial People's Hospital - Nanjing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-04-25 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 1 |
What NCT06414460 shows while recruiting
NCT06414460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 1 condition, with Locally Advanced/Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ISM3412 is the first listed.
NCT06414460 lists 9 locations in 9 states (Colorado, Connecticut, Indiana).
Frequently Asked Questions
What is clinical trial NCT06414460 about?
NCT06414460 is a clinical study titled "Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors". The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D o...
What is the current status of trial NCT06414460?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-04-25. Estimated completion is 2029-03-31.
What conditions does trial NCT06414460 study?
This clinical trial studies the following conditions: Locally Advanced/Metastatic Solid Tumors.
What interventions are being tested in trial NCT06414460?
The interventions under investigation include: ISM3412 (DRUG).
Who is sponsoring clinical trial NCT06414460?
This trial is sponsored by InSilico Medicine Hong Kong Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06414460 being conducted?
This trial has 9 study locations across Colorado, Connecticut, Indiana, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced/Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06414460's enrollment target sits among peer trials
80 673rd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI